Valuation
PharmaceuticalsLive · Yahoo FinancePrice
$0.66
52-Week Range
Decision Context
Altman Z-Score indicates financial distress risk. Review debt levels and cash runway before any position sizing decision.
Based on filing period ending Jun 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.63%
Accommodative
10-Year Treasury
4.60%
2026-07-01
Unemployment
4.1%
Near full employment
CPI Index
332.8
2026-07-01
M2 Money Supply
$23.2T
2026-06-01
The Federal Funds rate stands at 3.63% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.60%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.1%; Industrial production index is at 103.0; M2 money supply is $23.2T; CPI index stands at 332.8.
SWOT Analysis — OTLK
Inflationary BoomStrengths
Revenue: $8.1M (+163.8% YoY) — Revenue grew 164% — the company sold more goods or services than the prior year.
EPS (Diluted): $-1.79 (+55.9% YoY) — Negative EPS — the company recorded a loss on a per-share basis.
Operating Cash Flow: -$51.8M (+24.7% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.
Net Income: -$62.4M (+17.2% YoY) — The company posted a net loss — total expenses exceeded total revenue.
Weaknesses
Total Assets: $18.6M (-35.5% YoY) — Total assets shrank 36% — the balance sheet contracted.
R&D spending is 334% of revenue — heavy investment in future growth, but also a drag on current profitability.
Opportunities
No clear opportunities identified at this time.
Threats
Net loss of $62.4M — the company spent more than it earned. Investors should monitor the path to profitability.
Negative operating cash flow of $51.8M — the core business consumed more cash than it generated.
Total liabilities are 273% of total assets — the balance sheet is heavily leveraged with limited equity cushion.
Current ratio of 0.38x — short-term liabilities exceed current assets, which could create near-term liquidity pressure.
Financial Charts
Year-over-Year Changes
Revenue
$8.1M
was $3.1M
Revenue grew 164% — the company sold more goods or services than the prior year.
EPS (Diluted)
$-1.79
was $-4.06
Negative EPS — the company recorded a loss on a per-share basis.
Total Assets
$18.6M
was $28.8M
Total assets shrank 36% — the balance sheet contracted.
Operating Cash Flow
-$51.8M
was -$68.8M
Negative operating cash flow — the business consumed more cash than it produced from operations.
Net Income
-$62.4M
was -$75.4M
The company posted a net loss — total expenses exceeded total revenue.
Risk Flags
4 high · 0 medium · 1 low- ⚠ High
Net loss of $62.4M — the company spent more than it earned. Investors should monitor the path to profitability.
- ⚠ High
Negative operating cash flow of $51.8M — the core business consumed more cash than it generated.
- ⚠ High
Total liabilities are 273% of total assets — the balance sheet is heavily leveraged with limited equity cushion.
- ⚠ High
Current ratio of 0.38x — short-term liabilities exceed current assets, which could create near-term liquidity pressure.
- ○ Low
R&D spending is 334% of revenue — heavy investment in future growth, but also a drag on current profitability.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubFiling History — OTLK
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade OTLK
Links open broker research pages. Not an endorsement or recommendation.
Research OUTLOOK THERAPEUTICS, INC.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.